ArticleThe Journal of clinical investigation2023

Therapeutic targeting of metabolic vulnerabilities in cancers with MLL3/4-COMPASS epigenetic regulator mutations.

Zibo Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.